Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B

Journal of Gastroenterology

Volumn 48, Issue 3, 2013, Pages 397-404

  Enomoto, Masaru ^a   Nishiguchi, Shuhei ^b   Tamori, Akihiro ^a   Kobayashi, Sawako ^a   Sakaguchi, Hiroki ^a   Shiomi, Susumu ^c   Kim, Soo Ryang ^d   Enomoto, Hirayuki ^b   Saito, Masaki ^b   Imanishi, Hiroyasu ^b   Kawada, Norifumi ^a  

^a School of Medicine   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KOBE ASAHI HOSPITAL   (Japan)

Author keywords

Chronic hepatitis B; Entecavir; Genotypes; Interferon a; Sequential therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; JAPANESE; LIVER BIOPSY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOP CODON; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879636610     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0645-5     Document Type: Article

References (38)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359: 1486-500.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373: 582-92.
3. Iloeje U, Yang H, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130: 678-86.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295: 65-73.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50: 661-2.
6. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50: 227-42.
7. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2: 263-83.
8. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365: 123-9.
9. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352: 2682-95.
10. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology. 2001;34: 573-7.
11. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2006;23: 99-106.
12. Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Soufleris K, et al. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol. 2007;22: 1582-8.
13. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother. 2006;58: 1031-5.
14. Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Morikawa H, Jomura H, et al. Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res. 2007;27: 201-7.
15. Minami M, Okanoue T. Management of HBV infection in Japan. Hepatol Res 2007; 37(s1):S79-82.
16. Okuse C, Yotsuyanagi H, Yamada N, Okamoto M, Ikeda H, Kobayashi M, et al. Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2010;40: 461-9.
17. Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A, et al. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J Viral Hepat. 2011;18: 580-6.
18. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology. 2001; 34: 590-4.
19. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab. 2006;52: 43-7.
20. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B. N Engl J Med. 2006;354: 1001-10.
21. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAgnegative chronic hepatitis B. N Engl J Med. 2006;354: 1011-20.
22. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359: 2442-55.
23. Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40: 439-45.
24. Rokuhara A, Tanaka E, Matsumoto A, Kimura T, Yamaura T, Orii K, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat. 2003;10: 324-30.
25. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol. 2005;75: 235-9.
26. Hochberger S, Althof D. Gallegos de Schrott R, Nachbaur N, Röck H, Leying H. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/ COBAS TaqMan system. J Clin Virol. 2006;35: 373-80.
27. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods. 1999;80: 97-112.
28. Tadokoro K, Suzuki F, Kobayashi M, Yamaguchi T, Nagano M, Egashira T, et al. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. J Virol Methods. 2011;171: 67-73.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24: 289-93.
30. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr. Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa- 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323: 295-301.
31. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102: 2091-7.
32. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13: 29-60.
33. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998;102: 968-75.
34. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49: 1503-14.
35. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52: 1251-7.
36. Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t)ide analogs in patients with chronic hepatitis B. Hepatol Res. 2012;42: 139-49.
37. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40: 1-7.
38. Suzuki F, Arase Y, Akuta N, Tsubota A, Suzuki Y, Sezaki H, et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol. 2004;39: 969-74.